Liothyronine I 131 ( DrugBank: Liothyronine, Liothyronine I 131 )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 210 | Single Ventricle | 1 |
| 212 | Tricuspid atresia | 1 |
210. Single Ventricle
Clinical trials : 51 / Drugs : 53 - (DrugBank : 22) / Drug target genes : 32 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004828 (ClinicalTrials.gov) | December 1994 | 24/2/2000 | Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure | Tricuspid Atresia;Heart Defects, Congenital | Drug: liothyronine I 131 | FDA Office of Orphan Products Development | Children's Hospital and Health Center | Completed | N/A | 17 Years | Both | 28 | Phase 1 | NULL |
212. Tricuspid atresia
Clinical trials : 5 / Drugs : 6 - (DrugBank : 6) / Drug target genes : 8 - Drug target pathways : 12
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004828 (ClinicalTrials.gov) | December 1994 | 24/2/2000 | Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure | Tricuspid Atresia;Heart Defects, Congenital | Drug: liothyronine I 131 | FDA Office of Orphan Products Development | Children's Hospital and Health Center | Completed | N/A | 17 Years | Both | 28 | Phase 1 | NULL |